ELISA/assay

Human Protectin ELISA Kit

MBS730752

48-Strip-Wells-(Comp

470 USD

ELISA Kit

Human Protectin ELISA Kit

Protectin

CD59 glycoprotein preproprotein; CD59 glycoprotein; CD59 glycoprotein; protectin; 1F5 antigen; MEM43 antigen; Ly-6-like protein; T cell-activating protein; human leukocyte antigen MIC11; lymphocytic antigen CD59/MEM43; 20 kDa homologous restriction factor; membrane inhibitor of reactive lysis; membrane attack complex inhibition factor; membrane attack complex (MAC) inhibition factor; surface anitgen recognized by monoclonal antibody 16.3A5; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); CD59 molecule, complement regulatory protein; 1F5 antigen; 20 kDa homologous restriction factor; HRF-20; HRF20; MAC-inhibitory protein; MAC-IP; MEM43 antigen; Membrane attack complex inhibition factor; MACIF; Membrane inhibitor of reactive lysis; MIRL; Protectin; CD_antigen: CD59

CD59

CD59; CD59; 1F5; EJ16; EJ30; EL32; G344; MIN1; MIN2; MIN3; MIRL; HRF20; MACIF; MEM43; MIC11; MSK21; 16.3A5; HRF-20; MAC-IP; p18-20; MIC11; MIN1; MIN2; MIN3; MSK21; HRF-20; HRF20; MAC-IP; MACIF; MIRL

CD59_HUMAN

Human

This assay has high sensitivity and excellent specificity for detection of CD59. No significant cross-reactivity or interference between CD59 and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between CD59 and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Assay Type: Competitive or Sandwich. Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Sensitivity: 1.0 pg/mL.

Intended Uses: This CD59 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human CD59. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Immunology

Princple of the assay: CD59 ELISA kit applies the quantitative sandwich enzyme immunoassay technique. The microtiter plate has been pre-coated with a monoclonal antibody specific for CD59. Standards or samples are then added to the microtiter plate wells and CD59 if present, will bind to the antibody pre-coated wells. In order to quantitatively determine the amount of CD59 present in the sample, a standardized preparation of horseradish peroxidase (HRP)-conjugated polyclonal antibody, specific for CD59 are added to each well to “sandwich” the CD59 immobilized on the plate. The microtiter plate undergoes incubation, and then the wells are thoroughly washed to remove all unbound components. Next, substrate solutions are added to each well. The enzyme (HRP) and substrate are allowed to react over a short incubation period. Only those wells that contain CD59 and enzyme-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The CD59 concentration in each sample is interpolated from this standard curve.

42716299

NP_976076.1

NM_203331.2

14,177 Da

Arf6 Trafficking Events Pathway (137954); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); Complement Cascade Pathway (106405); Hematopoietic Cell Lineage Pathway (83078); Hematopoietic Cell Lineage Pathway (489); Immune System Pathway (106386); Innate Immune System Pathway (106387); Regulation Of Complement Cascade Pathway (576254)

This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. [provided by RefSeq, Jul 2008]

CD59: Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase. Defects in CD59 are the cause of CD59 deficiency (CD59D). Protein type: Membrane protein, GPI anchor. Chromosomal Location of Human Ortholog: 11p13. Cellular Component: anchored to external side of plasma membrane; extracellular space; compact myelin; focal adhesion; cell surface; membrane; extracellular region; plasma membrane; vesicle; sarcolemma. Molecular Function: complement binding; protein binding. Biological Process: cell activation; cell surface receptor linked signal transduction; regulation of complement activation; negative regulation of activation of membrane attack complex; innate immune response; positive regulation of T cell proliferation; blood coagulation; negative regulation of apoptosis. Disease: Hemolytic Anemia, Cd59-mediated, With Or Without Immune-mediated Polyneuropathy

48-Strip-Wells-(Competitive)

470 USD

48-Strip-Wells-(Sandwich)

470

96-Strip-Wells-(Competitive)

675

96-Strip-Wells-(Sandwich)

675